+29.1%
MRNA vs SBAC
-11.3%
+40.5%
-86.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | SBAC | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -2.8% | +3.6% | +1.4% |
| 7D | -8.2% | -5.3% | -3.0% | -7.1% |
| 30D | +125.6% | +0.4% | +125.2% | +125.5% |
| 3M | +197.1% | -11.9% | +209.0% | +203.5% |
| 6M | +148.5% | -4.5% | +153.0% | +149.0% |
| YTD | +363.3% | -4.3% | +367.6% | +362.4% |
| 1Y | +462.0% | -3.9% | +465.9% | +461.0% |
| All | +29.1% | -11.3% | +40.5% | +34.7% |
Cumulative growth
Daily Returns
Daily percentage return beside SBAC.
Daily Out/Under-Performance
Portfolio return minus SBAC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × SBAC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded SBAC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling